Previous 10 | Next 10 |
2023-07-17 08:06:31 ET Summary FPI-2265 is being explored in patients with metastatic castration-resistant prostate cancer in the ongoing phase 2 TATCIST trial; Results from this study are expected to be released Q1 of 2024. The global metastatic castrate resistant prostate cancer...
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R Canada NewsWire Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Co...
Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit Canada NewsWire HAMILTON, ON and BOSTON , June 16, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-g...
Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference Canada NewsWire HAMILTON, ON and BOSTON , May 31, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiop...
2023-05-11 11:56:23 ET Fusion Pharmaceuticals press release ( NASDAQ: FUSN ): Q1 GAAP EPS of -$0.45 misses by $0.23 . Cash, cash equivalents and marketable securities were $238.2 million as of March 31, 2023. In addition, subsequent to March 31, 2023, the Company&...
Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates Canada NewsWire FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the...
Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day Canada NewsWire HAMILTON , ON and BOSTON , May 9, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on develop...
Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer Canada NewsWire Facility is on track to be fully operational in 2024 HAMILTON, ON , May 2, 2023 /CNW/ -- Fusion Pharmaceu...
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting Canada NewsWire FPI-2059 induces tumor growth inhibition in colorectal tumor model TEM-1 and EGFRvIII demonstrate po...
2023-04-14 05:21:39 ET Summary Fusion Pharmaceuticals counts JNJ among its founding funders. They have an early stage pipeline of interesting targeted radiopharmaceuticals. Once they have data, I will probably be more interested. Fusion Pharmaceuticals ( FUSN ) d...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...